drugset / Trial / NCT02387983

Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

NCT02387983

Phase 1 Completed 65 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of oral posaconazole tablets in Chinese participants at high risk for invasive fungal infections. Neutropenic participants undergoing chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes will be enrolled in the study.

Timeline

Start
2015-05-06
Primary completion
2016-05-02
Completion
2016-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Posaconazole Small molecule 300 mg Oral